Extramedullary hematopoiesis in myeloproliferative neoplasms: Pathophysiology and treatment strategies

被引:2
|
作者
Chernak, Brian J. [1 ,2 ]
Rampal, Raajit K. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Leukemia, 1275 York Ave, New York, NY 10021 USA
[2] NewYork Presbyterian Weill Cornell Med Ctr, Dept Med, New York, NY 10021 USA
关键词
CHRONIC IDIOPATHIC MYELOFIBROSIS; EXTRA-MEDULLARY HEMATOPOIESIS; AGNOGENIC MYELOID METAPLASIA; INTERNATIONAL-WORKING-GROUP; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; RESPONSE CRITERIA; THERAPY; RUXOLITINIB; EFFICACY;
D O I
10.1016/bs.ircmb.2021.07.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Extramedullary hematopoiesis (EMH) is often a physiologic response to ineffective marrow production of hematologic cells. While this can be found incidentally in various physiologic and pathophysiologic states, the myeloproliferative neoplasms (MPNs) are some of the most common underlying conditions found in patients with EMH. Although this process can assist with hematologic production in defective states, the burden of EMH can lead to symptomatic discomfort and mechanical obstructive complications, most commonly in the spleen and liver. Here we describe the pathophysiology of EMH, treatment options, including medical, surgical and radiation-based approaches.
引用
收藏
页码:97 / 116
页数:20
相关论文
共 50 条
  • [41] Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients
    Fan, N.
    Lavu, S.
    Hanson, C. A.
    Tefferi, A.
    BLOOD CANCER JOURNAL, 2018, 8
  • [42] Myeloproliferative neoplasms - Update on diagnosis and treatment
    Meyer, Sara C.
    Drexler, Beatrice
    Skoda, Radek C.
    THERAPEUTISCHE UMSCHAU, 2019, 76 (09) : 487 - 495
  • [43] Developments in the Understanding and Treatment of myeloproliferative Neoplasms
    Schmidt, Stefan
    Wolf, Dominik
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2022, 147 (06) : 306 - 311
  • [44] Bomedemstat as an investigative treatment for myeloproliferative neoplasms
    Rienhoff Jr, Hugh Young
    Gill, Harinder
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, 32 (10) : 879 - 886
  • [45] The role of ruxolitinib in the treatment of myeloproliferative neoplasms
    Soret, Juliette
    Kiladjian, Jean-Jacques
    BULLETIN DU CANCER, 2016, 103 (06) : S29 - S38
  • [46] Current therapies for classic myeloproliferative neoplasms: A focus on pathophysiology and supportive care
    Chung, Clement
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2023, 80 (22) : 1624 - 1636
  • [47] Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease
    How, Joan
    Zhou, Amy
    Oh, Stephen T.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2017, 8 (03) : 107 - 118
  • [48] Therapiestrategien bei myeloproliferativen NeoplasienTreatment strategies for myeloproliferative neoplasms
    Florian Heidel
    Die Onkologie, 2022, 28 (8) : 721 - 730
  • [49] Surgical treatment of an unusual case of pelvic extramedullary hematopoiesis
    Khen-Dunlop, Naziha
    Girot, Robert
    Brunelle, Francis
    Revillon, Yann
    Nihoul-Fekete, Claire
    Sarnacki, Sabine
    JOURNAL OF PEDIATRIC SURGERY, 2006, 41 (07) : e13 - e15
  • [50] Mass-forming extramedullary hematopoiesis of the spleen in a patient with CALR-mutated myeloproliferative neoplasm
    Ohtani, Haruo
    Tanoi, Tomohito
    Azuma, Kazuaki
    Takaku, Hideya
    Nagayama, Reizo
    Ito, Masafumi
    Nakamura, Naoya
    PATHOLOGY INTERNATIONAL, 2020, 70 (04) : 237 - 239